Tumor Mesenchymal Stem-Like Cell As a Prognostic Marker in Primary Glioblastoma

Overview

Journal Stem Cells Int

Publisher Wiley

Specialty Cell Biology

Date 2016 Mar 17

PMID 26981133

Citations 18

Authors

Seon-Jin Yoon

Jin-Kyoung Shim

Jong Hee Chang

Ju Hyung Moon

Tae-Hoon Roh

Kyoung Su Sung

Ji-Hyun Lee

Eui-Hyun Kim

Sun Ho Kim

Yong-Kil Hong

Su-Jae Lee

Yong-Min Huh

Seok-Gu Kang

Affiliations

Soon will be listed here.

Abstract

The isolation from brain tumors of tumor mesenchymal stem-like cells (tMSLCs) suggests that these cells play a role in creating a microenvironment for tumor initiation and progression. The clinical characteristics of patients with primary glioblastoma (pGBM) positive for tMSLCs have not been determined. This study analyzed samples from 82 patients with pGBM who had undergone tumor removal, pathological diagnosis, and isolation of tMSLC from April 2009 to October 2014. Survival, extent of resection, molecular markers, and tMSLC culture results were statistically evaluated. Median overall survival was 18.6 months, 15.0 months in tMSLC-positive patients and 29.5 months in tMSLC-negative patients (P = 0.014). Multivariate cox regression model showed isolation of tMSLC (OR = 2.5, 95% CI = 1.1~5.6, P = 0.021) showed poor outcome while larger extent of resection (OR = 0.5, 95% CI = 0.2~0.8, P = 0.011) has association with better outcome. The presence of tMSLCs isolated from the specimen of pGBM is associated with the survival of patient.

Citing Articles

Mesenchymal Stem-Like Cells Derived from the Ventricle More Effectively Enhance Invasiveness of Glioblastoma Than Those Derived from the Tumor.

Park J, Lee D, Shim J, Yoon S, Moon J, Kim E Yonsei Med J. 2023; 64(3):157-166.

PMID: 36825341 PMC: 9971438. DOI: 10.3349/ymj.2022.0430.

The peritumoral brain zone in glioblastoma: where we are and where we are going.

Giambra M, Di Cristofori A, Valtorta S, Manfrellotti R, Bigiogera V, Basso G J Neurosci Res. 2022; 101(2):199-216.

PMID: 36300592 PMC: 10091804. DOI: 10.1002/jnr.25134.

The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma.

Wang W, Lu Z, Wang M, Liu Z, Wu B, Yang C Front Immunol. 2022; 13:998236.

PMID: 36110851 PMC: 9468372. DOI: 10.3389/fimmu.2022.998236.

C5α secreted by tumor mesenchymal stem-like cells mediates resistance to 5-aminolevulinic acid-based photodynamic therapy against glioblastoma tumorspheres.

Park J, Oh S, Shim J, Ji Y, Moon J, Kim E J Cancer Res Clin Oncol. 2022; 149(8):4391-4402.

PMID: 36107247 DOI: 10.1007/s00432-022-04347-w.

Influence of the Amount of Fresh Specimen on the Isolation of Tumor Mesenchymal Stem-Like Cells from High-Grade Glioma.

Kong S, Yoo J, Lee D, Moon S, Sung K, Park S Yonsei Med J. 2021; 62(10):936-942.

PMID: 34558873 PMC: 8470561. DOI: 10.3349/ymj.2021.62.10.936.

References

Golebiewska A, Bougnaud S, Stieber D, Brons N, Vallar L, Hertel F . Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells. Brain. 2013; 136(Pt 5):1462-75. PMC: 3634193. DOI: 10.1093/brain/awt025. View

McGirt M, Chaichana K, Gathinji M, Attenello F, Than K, Olivi A . Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2008; 110(1):156-62. DOI: 10.3171/2008.4.17536. View

Freije W, Castro-Vargas F, Fang Z, Horvath S, Cloughesy T, Liau L . Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004; 64(18):6503-10. DOI: 10.1158/0008-5472.CAN-04-0452. View

Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A . Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015; 129(6):829-48. DOI: 10.1007/s00401-015-1432-1. View

Poste G, Fidler I . The pathogenesis of cancer metastasis. Nature. 1980; 283(5743):139-46. DOI: 10.1038/283139a0. View

Shen R, Mo Q, Schultz N, Seshan V, Olshen A, Huse J . Integrative subtype discovery in glioblastoma using iCluster. PLoS One. 2012; 7(4):e35236. PMC: 3335101. DOI: 10.1371/journal.pone.0035236. View

Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A . Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One. 2009; 4(11):e7752. PMC: 2771920. DOI: 10.1371/journal.pone.0007752. View

Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F . Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009; 27(25):4150-4. DOI: 10.1200/JCO.2009.21.9832. View

Kong B, Shin H, Kim S, Mok H, Shim J, Lee J . Increased in vivo angiogenic effect of glioma stromal mesenchymal stem-like cells on glioma cancer stem cells from patients with glioblastoma. Int J Oncol. 2013; 42(5):1754-62. DOI: 10.3892/ijo.2013.1856. View

10.

Phillips H, Kharbanda S, Chen R, Forrest W, Soriano R, Wu T . Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006; 9(3):157-73. DOI: 10.1016/j.ccr.2006.02.019. View

11.

Mognetti B, La Montagna G, Perrelli M, Pagliaro P, Penna C . Bone marrow mesenchymal stem cells increase motility of prostate cancer cells via production of stromal cell-derived factor-1α. J Cell Mol Med. 2013; 17(2):287-92. PMC: 3822591. DOI: 10.1111/jcmm.12010. View

12.

Kim Y, Jeon S, Sin G, Shim J, Kim B, Shin H . Existence of glioma stroma mesenchymal stemlike cells in Korean glioma specimens. Childs Nerv Syst. 2013; 29(4):549-63. DOI: 10.1007/s00381-012-1988-1. View

13.

Nakamura H, Makino K, Kuratsu J . Molecular and clinical analysis of glioblastoma with an oligodendroglial component (GBMO). Brain Tumor Pathol. 2011; 28(3):185-90. DOI: 10.1007/s10014-011-0039-z. View

14.

Tso C, Shintaku P, Chen J, Liu Q, Liu J, Chen Z . Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res. 2006; 4(9):607-19. DOI: 10.1158/1541-7786.MCR-06-0005. View

15.

Kong B, Park N, Shim J, Kim B, Shin H, Lee J . Isolation of glioma cancer stem cells in relation to histological grades in glioma specimens. Childs Nerv Syst. 2012; 29(2):217-29. DOI: 10.1007/s00381-012-1964-9. View

16.

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View

17.

Kang S, Shinojima N, Hossain A, Gumin J, Yong R, Colman H . Isolation and perivascular localization of mesenchymal stem cells from mouse brain. Neurosurgery. 2010; 67(3):711-20. PMC: 3644957. DOI: 10.1227/01.NEU.0000377859.06219.78. View

18.

Paget S . The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989; 8(2):98-101. View

19.

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315-7. DOI: 10.1080/14653240600855905. View

20.

Fallon K, Palmer C, Roth K, Nabors L, Wang W, Carpenter M . Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol. 2004; 63(4):314-22. DOI: 10.1093/jnen/63.4.314. View